-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target

Benzinga·03/14/2025 10:54:00
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and maintains $2 price target.